{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T08:38:22Z","timestamp":1792744702015,"version":"4.5.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:00:00Z","timestamp":1792713600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:00:00Z","timestamp":1792713600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharmacol. Rep"],"DOI":"10.1007\/s43440-026-00919-6","type":"journal-article","created":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T07:49:15Z","timestamp":1792741755000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Adverse events during cystic fibrosis transmembrane conductance regulator modulator therapy in children with cystic fibrosis: an observational study"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-9322-2627","authenticated-orcid":false,"given":"Marta","family":"Osi\u0144ska","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1172-6312","authenticated-orcid":false,"given":"Beata","family":"Naro\u017cna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0867-1717","authenticated-orcid":false,"given":"Ewa","family":"Sapiejka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-7547-3383","authenticated-orcid":false,"given":"Paulina","family":"Famulska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7448-3370","authenticated-orcid":false,"given":"Katarzyna","family":"T\u0105polska-J\u00f3\u017awiak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-9822-8289","authenticated-orcid":false,"given":"Anna","family":"Steinert-Dymecki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-0691-9454","authenticated-orcid":false,"given":"Aleksandra","family":"Koz\u0142owska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-8660-084X","authenticated-orcid":false,"given":"Maria","family":"J\u00f3\u017awiak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9666-1599","authenticated-orcid":false,"given":"Joanna","family":"Nowakowska-Lewicka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7272-5738","authenticated-orcid":false,"given":"Agnieszka","family":"Bienert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6724-1499","authenticated-orcid":false,"given":"Irena","family":"Wojsyk-Banaszak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,23]]},"reference":[{"key":"919_CR1","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1001\/jama.2023.8120","volume":"329","author":"T Ong","year":"2023","unstructured":"Ong T, Ramsey BW. Cystic Fibrosis: A Review. JAMA. 2023;329:1859\u201371.","journal-title":"JAMA"},{"key":"919_CR2","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1146\/annurev-med-042921-021447","volume":"74","author":"S Jia","year":"2023","unstructured":"Jia S, Taylor-Cousar JL. Cystic Fibrosis Modulator Therapies. Annu Rev Med. 2023;74:413\u201326.","journal-title":"Annu Rev Med"},{"key":"919_CR3","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1056\/NEJMoa1105185","volume":"365","author":"BW Ramsey","year":"2011","unstructured":"Ramsey BW, Davies J, McElvaney NG, Tullis E, Bell SC, D\u0159ev\u00ednek P, et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med. 2011;365:1663\u201372.","journal-title":"N Engl J Med"},{"key":"919_CR4","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1056\/NEJMoa1409547","volume":"373","author":"CE Wainwright","year":"2015","unstructured":"Wainwright CE, Elborn JS, Ramsey BW, Marigowda G, Huang X, Cipolli M, et al. Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR. N Engl J Med. 2015;373:220\u201331.","journal-title":"N Engl J Med"},{"key":"919_CR5","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.1056\/NEJMoa1709847","volume":"377","author":"SM Rowe","year":"2017","unstructured":"Rowe SM, Daines C, Ringshausen FC, Kerem E, Wilson J, Tullis E, et al. Tezacaftor-Ivacaftor in Residual-Function Heterozygotes with Cystic Fibrosis. N Engl J Med. 2017;377:2024\u201335.","journal-title":"N Engl J Med"},{"key":"919_CR6","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/S2213-2600(21)00454-9","volume":"10","author":"S Sutharsan","year":"2022","unstructured":"Sutharsan S, McKone EF, Downey DG, Duckers J, MacGregor G, Tullis E, et al. Efficacy and safety of elexacaftor plus tezacaftor plus ivacaftor versus tezacaftor plus ivacaftor in people with cystic fibrosis homozygous for F508del-CFTR: a 24-week, multicentre, randomised, double-blind, active-controlled, phase 3b trial. Lancet Respir Med. 2022;10:267\u201377.","journal-title":"Lancet Respir Med"},{"key":"919_CR7","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/S2213-2600(24)00411-9","volume":"13","author":"C Keating","year":"2025","unstructured":"Keating C, Yonker LM, Vermeulen F, Davies JC, Flume PA, De Boeck K, et al. Vanzacaftor-Tezacaftor-Deutivacaftor Versus Elexacaftor-Tezacaftor-Ivacaftor in Individuals with Cystic Fibrosis Aged\u2009\u2265\u200912 Years: Results from Two Randomized, Active-Controlled, Phase 3 Trials. Lancet Respir Med. 2025;13:256\u201371.","journal-title":"Lancet Respir Med"},{"key":"919_CR8","first-page":"100829","volume":"80","author":"C Martin","year":"2021","unstructured":"Martin C, Burnet E, Ronayette-Preira A, Mely L, Burgel PR, Chiron R, et al. Patient Perspectives Following Initiation of Elexacaftor-Tezacaftor-Ivacaftor in People with Cystic Fibrosis and Advanced Lung Disease. Respir Med Res. 2021;80:100829.","journal-title":"Respir Med Res"},{"key":"919_CR9","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1164\/rccm.202011-4153OC","volume":"204","author":"PR Burgel","year":"2021","unstructured":"Burgel PR, Durieu I, Chiron R, Mely L, Grenet D, Kessler R, et al. Rapid Improvement After Starting Elexacaftor-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and Advanced Pulmonary Disease. Am J Respir Crit Care Med. 2021;204:64\u201373.","journal-title":"Am J Respir Crit Care Med"},{"key":"919_CR10","doi-asserted-by":"publisher","first-page":"240045","DOI":"10.1183\/16000617.0045-2024","volume":"33","author":"I Fajac","year":"2024","unstructured":"Fajac I, Burgel PR, Martin C. New Drugs, New Challenges in Cystic Fibrosis Care. Eur Respir Rev. 2024;33:240045.","journal-title":"Eur Respir Rev"},{"key":"919_CR11","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.jcf.2024.09.010","volume":"24","author":"J O\u2019Connor","year":"2025","unstructured":"O\u2019Connor J, Nazareth D, Wat D, Southern KW, Frost F. Regulatory adverse drug reaction analyses support a temporal increase in psychiatric reactions after initiation of cystic fibrosis combination modulator therapies. J Cyst Fibros. 2025;24:30\u20132.","journal-title":"J Cyst Fibros"},{"issue":"Suppl 1","key":"919_CR12","doi-asserted-by":"publisher","first-page":"A10","DOI":"10.1093\/sleepadvances\/zpad035.028","volume":"4","author":"H Pham","year":"2023","unstructured":"Pham H, Ranganathan S, Vandeleur M. O028 Worsened sleep and mood after initiating elexacaftor\/tezacaftor\/ivacaftor treatment in children with cystic fibrosis. Sleep Adv. 2023;4(Suppl 1):A10.","journal-title":"Sleep Adv"},{"key":"919_CR13","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1016\/j.chest.2023.10.043","volume":"165","author":"S Graziano","year":"2024","unstructured":"Graziano S, Boldrini F, Pellicano GR, Milo F, Majo F, Cristiani L, et al. Longitudinal effects of elexacaftor\/tezacaftor\/ivacaftor: multidimensional assessment of neuropsychological side effects and physical and mental health outcomes in adolescents and adults. Chest. 2024;165:800\u20139.","journal-title":"Chest"},{"key":"919_CR14","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1164\/rccm.202308-1525OC","volume":"209","author":"B Ramsey","year":"2024","unstructured":"Ramsey B, Correll CU, DeMaso DR, McKone E, Tullis E, Taylor-Cousar JL, et al. Elexacaftor\/tezacaftor\/ivacaftor treatment and depression-related events. Am J Respir Crit Care Med. 2024;209:299\u2013306.","journal-title":"Am J Respir Crit Care Med"},{"key":"919_CR15","doi-asserted-by":"publisher","first-page":"114176","DOI":"10.1016\/j.jpeds.2024.114176","volume":"274","author":"V Terlizzi","year":"2024","unstructured":"Terlizzi V, Fevola C, Presti S, Castaldo A, Dacc\u00f2 V, Claut L, et al. Reported adverse events in a multicenter cohort of patients ages 6\u201318 years with cystic fibrosis and at least one F508del allele receiving elexacaftor\/tezacaftor\/ivacaftor. J Pediatr. 2024;274:114176.","journal-title":"J Pediatr"},{"key":"919_CR16","doi-asserted-by":"publisher","first-page":"2402435","DOI":"10.1183\/13993003.02435-2024","volume":"66","author":"MA Mall","year":"2025","unstructured":"Mall MA, Wainwright CE, Legg J, Chilvers M, Gartner S, Dittrich AM, et al. Elexacaftor\/tezacaftor\/ivacaftor in children aged\u2009\u2265\u20096 years with cystic fibrosis heterozygous for F508del and a minimal function mutation: results from a 96-week open-label extension study. Eur Respir J. 2025;66:2402435.","journal-title":"Eur Respir J"},{"key":"919_CR17","doi-asserted-by":"publisher","first-page":"4335","DOI":"10.3390\/jcm14124335","volume":"14","author":"F Lucca","year":"2025","unstructured":"Lucca F, Meneghelli I, Tridello G, Buniotto F, Cucchetto G, Volpi S, et al. Reported adverse events in patients with CF receiving treatment with elexacaftor\/tezacaftor\/ivacaftor: 5 years observational study. J Clin Med. 2025;14:4335.","journal-title":"J Clin Med"},{"key":"919_CR18","unstructured":"Ministry of Health. Statement on the funding of Kaftrio and Kalydeco for the treatment of cystic fibrosis under the emergency access to medicinal technologies procedure. Gov.pl. 2023. https:\/\/www.gov.pl\/attachment\/7ad3c2d8-ed7c-43fe-8517-cbbd5b006fc4."},{"key":"919_CR19","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1164\/rccm.202102-0509OC","volume":"203","author":"ET Zemanick","year":"2021","unstructured":"Zemanick ET, Taylor-Cousar JL, Davies J, Gibson RL, McKone EF, Scott S, et al. Phase 3 open-label study of elexacaftor\/tezacaftor\/ivacaftor in children 6\u201311 years with cystic fibrosis and at least one F508del allele. Am J Respir Crit Care Med. 2021;203:1522\u201332.","journal-title":"Am J Respir Crit Care Med"},{"key":"919_CR20","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1164\/rccm.202301-0084OC","volume":"208","author":"JL Goralski","year":"2023","unstructured":"Goralski JL, Hoppe JE, Mall MA, McKone EF, Ramsey BW, Davies JC, et al. Phase 3 open-label clinical trial of elexacaftor\/tezacaftor\/ivacaftor in children aged 2\u20135 years with cystic fibrosis and at least one F508del allele. Am J Respir Crit Care Med. 2023;208:59\u201367.","journal-title":"Am J Respir Crit Care Med"},{"key":"919_CR21","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1016\/j.jcf.2025.10.001","volume":"24","author":"A Castaldo","year":"2025","unstructured":"Castaldo A, Cimbalo C, Fevola C, Raia V, Terlizzi V, Gelzo M, et al. The treatment with elexacaftor\/tezacaftor\/ivacaftor significantly increases serum bilirubin and decreases blood platelets in children and adolescents with cystic fibrosis homozygous or double heterozygous for the F508del CFTR variant. J Cyst Fibros. 2025;24:1149\u201355.","journal-title":"J Cyst Fibros"},{"issue":"6","key":"919_CR22","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1002\/ppul.24319","volume":"54","author":"A Patterson","year":"2019","unstructured":"Patterson A, Autry E, Kuhn R, Wurth M. Ivacaftor drug desensitization. Pediatr Pulmonol. 2019;54(6):672\u20134. https:\/\/doi.org\/10.1002\/ppul.24319. Epub 2019 Mar 25. PMID: 30912311.","journal-title":"Pediatr Pulmonol"},{"key":"919_CR23","doi-asserted-by":"publisher","first-page":"e71681","DOI":"10.1002\/ppul.71681","volume":"61","author":"P Famulska","year":"2026","unstructured":"Famulska P, Wi\u0119ckowska B, Naro\u017cna B, Sapiejka E, Osi\u0144ska M, Musia\u0142 A, et al. Comparison of long-term effects of treatment of different CFTR modulators in people with cystic fibrosis. Pediatr Pulmonol. 2026;61:e71681.","journal-title":"Pediatr Pulmonol"},{"key":"919_CR24","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1164\/rccm.202202-0392OC","volume":"206","author":"MA Mall","year":"2022","unstructured":"Mall MA, Brugha R, Gartner S, Legg J, Moeller A, Mondejar-Lopez P, et al. Efficacy and safety of elexacaftor\/tezacaftor\/ivacaftor in children 6 through 11 years of age with cystic fibrosis heterozygous for F508del and a minimal function mutation: a phase 3b randomized placebo-controlled study. Am J Respir Crit Care Med. 2022;206:1361\u20139.","journal-title":"Am J Respir Crit Care Med"},{"key":"919_CR25","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/j.jcf.2019.06.009","volume":"18","author":"S Walker","year":"2019","unstructured":"Walker S, Flume P, McNamara J, Solomon M, VanDevanter D, Daines C, et al. Phase 3 Study of Tezacaftor in Combination with Ivacaftor in Children Aged 6\u201311 Years with Cystic Fibrosis. J Cyst Fibros. 2019;18:708\u201313.","journal-title":"J Cyst Fibros"}],"container-title":["Pharmacological Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43440-026-00919-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s43440-026-00919-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43440-026-00919-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T07:49:22Z","timestamp":1792741762000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s43440-026-00919-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,23]]},"references-count":25,"alternative-id":["919"],"URL":"https:\/\/doi.org\/10.1007\/s43440-026-00919-6","relation":{},"ISSN":["1734-1140","2299-5684"],"issn-type":[{"value":"1734-1140","type":"print"},{"value":"2299-5684","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,23]]},"assertion":[{"value":"23 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 October 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"MO, PF, KT-J, and IW-B received funding, travel support, and\/or lecture fees from Vertex Pharmaceuticals; IW-B also received consulting fees. These financial relationships had no influence on any aspect of the study. All other authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}